drugset / Trial / NCT06728072
Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer
Phase 2
Recruiting
97 enrolled
Virginia Commonwealth University
American Cancer Society, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a 2-arm, noncomparative phase 2 trial designed to evaluate treatment outcomes with or without the addition of ciprofloxacin, metronidazole, and aspirin to first-line chemotherapy for patients with stage IV colorectal cancer (CRC).
Timeline
- Start
- 2025-03-07
- Primary completion
- 2035-07-01
- Completion
- 2035-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aspirin | Small molecule | 81 mg | — |
| Subject | Ciprofloxacin | Small molecule | 500 mg | — |
| Subject | Metronidazole | Small molecule | 500 mg | — |